- Home
- SNV vs EXAS Comparison
SNV vs EXAS Comparison
Compare SNV & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNV
- EXAS
- Stock Information
- Founded
- SNV 1888
- EXAS 1995
- Country
- SNV United States
- EXAS United States
- Employees
- SNV N/A
- EXAS N/A
- Industry
- SNV Major Banks
- EXAS Medical Specialities
- Sector
- SNV Finance
- EXAS Health Care
- Exchange
- SNV Nasdaq
- EXAS Nasdaq
- Market Cap
- SNV 7.9B
- EXAS 8.8B
- IPO Year
- SNV N/A
- EXAS N/A
- Fundamental
- Price
- SNV $45.76
- EXAS $43.45
- Analyst Decision
- SNV Buy
- EXAS Strong Buy
- Analyst Count
- SNV 19
- EXAS 18
- Target Price
- SNV $58.68
- EXAS $70.59
- AVG Volume (30 Days)
- SNV 2.0M
- EXAS 1.9M
- Earning Date
- SNV 04-16-2025
- EXAS 05-01-2025
- Dividend Yield
- SNV 3.39%
- EXAS N/A
- EPS Growth
- SNV N/A
- EXAS N/A
- EPS
- SNV 3.03
- EXAS N/A
- Revenue
- SNV $1,852,496,000.00
- EXAS $2,758,867,000.00
- Revenue This Year
- SNV $28.53
- EXAS $12.98
- Revenue Next Year
- SNV $6.59
- EXAS $12.96
- P/E Ratio
- SNV $15.19
- EXAS N/A
- Revenue Growth
- SNV N/A
- EXAS 10.37
- 52 Week Low
- SNV $33.44
- EXAS $40.62
- 52 Week High
- SNV $59.92
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- SNV 38.33
- EXAS 37.98
- Support Level
- SNV $46.55
- EXAS $42.51
- Resistance Level
- SNV $49.53
- EXAS $47.23
- Average True Range (ATR)
- SNV 1.35
- EXAS 1.63
- MACD
- SNV 0.20
- EXAS 0.06
- Stochastic Oscillator
- SNV 31.61
- EXAS 26.89
About SNV Synovus Financial Corp.
Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products & services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, & international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.